60 results about "Prevotella" patented technology

The invention discloses a multiple primer group for detecting pathogens of reproductive system diseases and a kit thereof. The kit comprises a combination of amplification primers and fluorescent probes of 10 pathogens, the pathogens comprise molluscum contagiosum virus, Snethia bacteria, gardnerella vaginalis, prevotella genus, campylobacter genus, giant globules genus, Atortobacter vaginalis, lactobacillus jensenii, lactobacillus crispatus and inert lactobacillus. The kit contains UDG enzyme and is used for preventing pollution of a PCR amplification product, and the accuracy of a detection result is ensured. The kit provided by the invention contains an internal reference control, can display the occurrence of false negative, and is used for monitoring the collection, transportation, extraction and amplification processes of a to-be-detected sample. According to the kit, the specificity is 100%, the detection sensitivity reaches 10 copies / mL, the specificity is good, and the detection efficiency is high. The kit is used for identifying the reproductive system disease pathogens of a to-be-detected sample, the to-be-detected sample can be vaginal secretion, the operation steps are simple, and the detection period is short.

The invention discloses an esophageal adenocarcinoma plasma circulation microbial marker combination, a reagent, a kit, a risk prediction model and application thereof, and belongs to the cross technical field of liquid biopsy and microbiomics. The esophageal adenocarcinoma plasma circulating microbial marker combination disclosed by the invention comprises enterobacteriaceae, cilia, prevotella, ackermania, lactobacillus fermentum and streptococcus. When the esophageal adenocarcinoma plasma circulating microbial marker combination is used for verifying esophageal adenocarcinoma patients and healthy controls, the AUC is 0.952, the sensitivity is 100%, the specificity is 80.00%, the accuracy is 91.43%, the positive predictive value is 86.96%, and the negative predictive value is 100%; the esophageal adenocarcinoma plasma circulating microbial marker combination can effectively distinguish esophageal adenocarcinoma patients from healthy people, is suitable for early screening of esophageal adenocarcinoma, and has remarkable clinical screening application value.

The invention belongs to the technical field of biological medicine and analysis, and provides an esophageal cancer early screening model based on oral microorganisms and a construction method thereof. The model is an oral cavity microbial flora as follows: Prevotella, Granulicalala, Rothia, Prevotella, Blauria, Abiotrophia, Peptostreptococcus, Actinomycetes, Burkholderia, Akkermansia, Fudania, Kineothrix, Bacillus, Duncaniella, and Eisenbergiella, and the oral cavity microbial flora is selected from the group consisting of the following microbial flora: the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora, the oral cavity microbial flora and the oral cavity microbial flora. By identifying non-invasive biomarkers, early-stage asymptomatic esophageal cancer patients can be found.

The invention belongs to the field of molecular biological detection, and provides a joint detection composition which mainly utilizes a multiple fluorescent PCR analysis method to detect related pathogens, so that detection and distinguishing of at least four of clostridium praerzii, eubacterium rectum, streptococcus salivarius, clostridium tenella, prevotella and escherichia coli are simultaneously realized in a single-tube reaction system. Meanwhile, the detection sensitivity of the composition is higher and reaches 500 copies / mL, and the detection is more accurate.

According to the probiotic composition and the application of the probiotic composition in preparation of products for preventing and treating vagina inflammation, the probiotic composition composed of lactobacillus gasseri B13.52 and lactobacillus mucus B14.46 screened from vaginal secretion of healthy women can effectively inhibit growth of escherichia coli, gardnerella and prevotella; the secretion of proinflammatory factors in vaginal epithelial cells can be obviously reduced, so that an anti-inflammatory effect is achieved.

The disclosure belongs to the technical field of biomedicine and analysis, and provides an early screening model for esophageal cancer based on oral microbiota and a construction method therefor. The model uses the following oral microbiota as markers: Prevotella, Granulicatella, Rothia, Prevotellamassilia, Blautia, Abiotrophia, Peptostreptococcus, Actinomyces, Burkholderia, Akkermansia, Fudania, Kineothrix, Bacillus, Duncaniella, and Eisenbergiella. The disclosure detects early asymptomatic esophageal cancer patients by identifying non-invasive biomarkers.

To provide a citrulline-reducing agent for intraoral use.SOLUTION: The present invention provides a citrulline-reducing agent for intraoral use that contains vitamin B6. The citrulline-reducing agent for intraoral use inhibits citrulline production and / or secretion by intraoral bacteria such as those belonging to Porphyromonas, Fusobacterium, Prevotella, Veillonella, Treponema, or Streptococcus.SELECTED DRAWING: None

The invention belongs to the technical field of biology, and discloses a polypeptide derived from a deep sea ecological environment, an application of the polypeptide in preparation of an antibacterial preparation and an antibacterial drug. According to the application of the polypeptide disclosed by the invention in the preparation of the antibacterial preparation, the polypeptide comprises one or more of amino acid fragments with sequences shown as SEQ ID NO: 1-9, the compound has good bacteriostatic or bactericidal activity on one or more of escherichia coli, halomonas aeruginosa, acinetobacter picoteri, staphylococcus aureus, linear preristeria, klebsiella pneumoniae and vibrio parahaemolyticus, and has extremely low toxicity on mammalian cells under an effective concentration. The compound has excellent bacteriostatic activity, bacteriostatic broad-spectrum property and biocompatibility, and has very excellent application prospects in multiple fields such as food preservation, agricultural disease prevention and control, feed additives and the like.

This invention belongs to the field of pharmaceutical technology, and relates to the use of a combination of sour cherry powder and celery seed powder, and complexes containing this composition. Specifically, the sour cherry powder and celery seed powder composition is used in the preparation of drugs for treating or regulating intestinal flora imbalance caused by hyperuricemia. The preparation method of this composition is as follows: pitting sour cherries, freezing them separately with liquid nitrogen, grinding them into powder using a pulverizer, and sieving them separately to obtain sour cherry powder and celery seed powder; mixing the obtained sour cherry powder and celery seed powder at a ratio of (0.5~3):1. This invention discusses the diversity, richness, and evenness of intestinal flora through diversity analysis, community bar chart analysis, and Venn diagram analysis. The results show that this composition can increase beneficial bacteria (Prevotella, Mulliez, Lactobacillus, etc.), reduce harmful bacteria (Alternaria), improve the structure of intestinal flora, and maintain the balance of intestinal flora.

The application discloses a kind of adolescent autism intestinal microorganism marker and application thereof, belong to the field of biological medicine.The microorganism marker includes one or more of Ruminococcus gnavus, Streptococcus thermophilus, Streptococcus salivarius, Butte's intestinal bacillus, pet big anaerobic clavulanic acid bacteria and Prevotella pittmanniae.The application provides a kind of product (such as kit), including detection reagent for detecting the relative abundance of the microorganism marker.The product provided by the application has good feasibility and accuracy, and can effectively evaluate whether adolescent has the risk of autism, provides a new tool for clinical diagnosis.

The present invention discloses a β-1,4-endoxylanase derived from the metagenome of Asian elephant feces, its encoding gene and applications, which relates to the technical field of genetic engineering. The genome of a Prevotella bacterium with a completeness of 97.47% and a contamination rate of 0 was assembled by using metagenomic binning technology. The β-1,4-endoxylanase (EC 3.2.1.8) gene was obtained through annotation in the KEGG Enzyme database. The nucleotide sequence of the β-1,4-endoxylanase encoding gene is shown as SEQ ID NO.3, and its amino acid sequence is shown as SEQ ID NO.4. Compared with the β-1,4-endoxylanase derived from fungi, this enzyme has good thermal stability and pH stability, can significantly increase the growth rate of reducing sugars in the in vitro enzymatic hydrolysis of soybean meal, is beneficial to the pretreatment of soybean meal raw materials, and has application value for the preparation of feed using soybean meal.

This invention relates to the field of gene detection technology, specifically to a primer set and its application, and a training method for a bacterial vaginosis diagnostic model. The primer set, used for diagnosing bacterial vaginosis, includes specific primers for specifically amplifying target regions of the following pathogens: *Atopobacterium vaginalis*, *Gardnerella vaginalis*, *Cyclophorus 1*, *Cyclophorus 2*, *Bacterial Vaginosis-Associated Bacteria 2*, *Animal Curvularia clarithii*, *Animal Curvularia emblica*, *Prevotella 2*, *Lactobacillus curvularia*, *Lactobacillus indolentus*, *Lactobacillus gasseri*, and *Lactobacillus janniae*. This invention also provides the application of this primer set and a training method for a bacterial vaginosis diagnostic model. Using this primer set, high-throughput sequencing can be performed on test samples, simultaneously detecting 12 target pathogens, and further constructing a bacterial vaginosis diagnostic model, which can be used for the clinical diagnosis of bacterial vaginosis with good specificity and sensitivity.

The invention discloses an anaerobic bacterium co-culture device and application thereof.The anaerobic bacterium co-culture device comprises a first screw injector 1 and a second screw injector 8, the first screw injector 1 is sequentially connected with a first Luer external thread adapter 2, a first hose 3, a filter membrane clamp 4, a second hose 5, a second Luer external thread adapter 6 and the second screw injector 8, and the first Luer external thread adapter 2, the first hose 3, the filter membrane clamp 4, the second hose 5, the second Luer external thread adapter 6 and the second screw injector 8 are sequentially connected; and a filter membrane 7 is arranged in the filter membrane clamp 4. The anaerobic bacteria co-culture device is simple in structure, low in cost and convenient to use, can easily simulate an anaerobic environment and co-culture anaerobic bacteria without anaerobic culture equipment, can well culture two different species of bacteria in the same liquid environment without cross contamination, is suitable for co-culture of various common anaerobic bacteria, and has a wide application prospect. Such as salmonella typhimurium, bifidobacterium breve, fecal bacillus przewalskii, ackermania or prevotella. The method has great benefits for the initial research of related research projects of bacterial interaction.

The invention discloses a kit for detecting intestinal core bacteria by a TaqMan real-time fluorescent quantitative PCR (Polymerase Chain Reaction) method, and belongs to the technical field of kits. The kit disclosed by the invention comprises standard positive templates of nine common intestinal core bacteria and nine groups of specific primers and probes which are required in a PCR amplification process and correspond to the standard positive templates. The kit disclosed by the invention is simple, convenient and rapid to operate; the specificity is good and the sensitivity is high; complicated raw information data analysis does not need to be carried out; the intestinal core bacteria can be detected and quantified without high-throughput sequencing, and three bacteria can be detected in one reaction hole, so that the cost is greatly reduced. The kit provided by the invention can be used for rapidly and quantitatively detecting nine intestinal core bacteria including bifidobacterium, lactobacillus, prevotella, bacteroides and the like, can partially replace a high-throughput detection method which is higher in cost and more complicated to operate according to research and diagnosis purposes, and is suitable for being widely popularized in clinical detection and laboratory research.

The invention relates to the technical field of medicine, and particularly discloses a liver cirrhosis specific intestinal flora marker composition and application of the liver cirrhosis specific intestinal flora marker composition in noninvasive diagnosis. The intestinal microbial flora is selected from the group consisting of clostridium, Bacteroides, Thalictrum, Wehonor genus, Streptococcus genus, Klebsiella genus, and Prevotella genus; according to the method, a non-invasive solution is provided for screening and diagnosis of liver cirrhosis by detecting a synergistic change mode of specific florae such as clostridium, bacteroides, thickenella, prevotella, Wehonor, streptococcus and klebsiella in an excrement sample; the limitation that traditional liver needle biopsy is invasive and imaging examination is insensitive to early-stage lesions is avoided.

The present invention discloses a meso-diaminopimelate dehydrogenase mutant of Prevotella and its application. The modification method of the present invention designs the optimal mutant through combinatorial mutation, modifies the protein of PtDAPDH, overcomes the limitation of the low catalytic activity of the previous wild-type enzyme, and finally obtains the optimal mutant T5 (PtDAPDH<supgt;N13E / S90R / P254A< / supgt;), whose catalytic half-life and D-p-hydroxyphenylglycine production are 1.10 times and 2.67 times that of the wild-type respectively. Using L-p-hydroxyphenylglycine as the substrate, the production in a 0.1 L shake flask after conversion is 3.2 g / L, and the conversion rate is 32%. With high catalytic efficiency and production intensity, it greatly reduces the previous high cell mass and expensive substrate cost, laying a foundation for the industrial production of D-p-hydroxyphenylglycine.

The invention relates to the technical field of gene detection, in particular to a primer group and application thereof, and a training method of a bacterial vaginitis diagnosis model. The primer group is used for diagnosing bacterial vaginitis and comprises a specific primer, and the target areas are used for specifically amplifying the following target pathogens: Atortobacterium vaginalis, Gardneria vaginalis, type 1 giant coccus, type 2 giant coccus, bacterial vaginitis related bacteria 2, campylobacter kirschengensis, campylobacter pudicus, two-way prevotella, Lactobacillus crispatus, Lactobacillus inervis, Lactobacillus gasseri and Lactobacillus jensenii. The invention also provides application of the primer group and a training method of a bacterial vaginitis diagnosis model. The primer group can be used for carrying out high-throughput sequencing on a to-be-detected sample, 12 target pathogens can be detected at the same time, a bacterial vaginitis diagnosis model is further constructed, and the primer group can be used for clinical diagnosis of bacterial vaginitis and has good specificity and sensitivity.

Drug-inducible, tunable, and multiplexable Clustered Regularly Interspaced Short Palindromic Repeats from Prevotella and Francisella 1 (Cpf1)-based activators, and methods of use thereof.

The invention discloses an intestinal flora marker related to metabolic heterogeneity of azathiopurine (AZA) and application of the intestinal flora marker, and belongs to the technical field of personalized drug treatment of inflammatory bowel diseases (IBD). In particular, the invention finds that a specific intestinal flora marker is significantly related to the level of an AZA active metabolite 6-thiopurine nucleotide (6-TGN). For example, the prevotella abundance can be used for distinguishing IBD patients with different 6-TGN exposure levels, has an indication effect on the in-vivo 6-TGN concentration, and has an important application value in thiazopurine therapeutic drug monitoring (TDM). In addition, clostridium species Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are significantly enriched in a 6-TGN high-exposure patient group, and the microbiome of the clostridium sp.OF09-36 and Clostridium sp.AF32-12BH encodes enzyme genes participating in purine metabolism, such as GMPS, HPRT, IMPDH and the like, which indicate that the Clostridium sp.OF09-36 and Clostridium sp.AF32-12BH are potential intestinal flora targets for regulating and controlling AZA metabolism. The intestinal flora marker provided by the invention provides a new biomarker and an intervention target for optimization and adjustment of AZA therapeutic dose and individualized precise treatment of IBD.

This invention belongs to the fields of bioinformatics and medical testing technology, specifically relating to a combination of biomarkers related to the postoperative prognosis of colorectal cancer and their application and prediction system. This invention, through 16S rRNA gene sequencing of tumor mucosal samples from colorectal cancer patients, combined with long-term postoperative follow-up data and screening, found that *Peptostreptococcus*, *Fusobacterium*, *Bacteroides*, *Porphyromonas*, and *Prevotella* are closely related to postoperative recurrence of colorectal cancer, with an AUC of 0.81 for assessing postoperative recurrence. Based on this, this invention conducts non-targeted metabolomics analysis, finding that combining alanine glutamate, putrescine, arginine, histidine, and sebacic acid with the above microbial biomarkers can improve the AUC to 0.91, significantly enhancing accuracy, specificity, and precision. This enables prognostic stratification of recurrence-free survival in colorectal cancer patients, demonstrating higher predictive efficacy and stability.

The invention discloses a biomarker group for predicting NSCLC immunotherapy prognosis based on tissue resident Prevotella and application of the biomarker group. The method comprises the following steps: detecting the enrichment abundance value of a paracarcinoma tissue resident bacterial biomarker Prevotella in combination with clinical indexes Ca, Age, HGB, HCT and ALT; a comprehensive analysis method for interaction of the host and the tumor microorganisms is formed; and establishing a scoring formula of the NSCLC immunotherapy prognosis prediction model for calculation, and if the RiskScore score is higher than the optimal cutoff value 720.7 of the combined prediction model, judging that the patient is sensitive to immunotherapy. Compared with various single markers, the marker group and the application thereof provided by the invention have the advantages that the prognosis of the patient is more accurately predicted, and clinical treatment can be conveniently guided. According to the combined prediction prognosis method considering multiple variables, the biological difference of different patients can be better reflected, so that the accuracy and the universality of prognosis prediction are improved.

The application belongs to the technical field of biological detection, and particularly relates to a biomarker for idiopathic hyperaldosteronism and application thereof. The biomarker for idiopathic hyperaldosteronism is human intestinal microorganisms, and the human intestinal microorganisms include one or more combinations of Desulfovibrionales, Peptostreptococcaceae, Ruminococcus or Prevotellaceae. A diagnostic model constructed based on the biomarker (two or more of Desulfovibrionales, Peptostreptococcus, Ruminococcus or Prevotella) provided by the application can be used for auxiliary diagnosis of idiopathic hyperaldosteronism, and has high accuracy, excellent sensitivity and good specificity.

The invention provides for methods of detecting and improving microbial diversity in a subject's gastrointestinal system.

The invention discloses a preparation method of a ficus microcarpa extract and application of the ficus microcarpa extract in intestinal flora disorder caused by circadian rhythm disorder. Pharmacological experiments prove that the ficus striata flavone has a remarkable regulating effect in a circadian rhythm disorder injury model: the ficus striata flavone can be used for effectively solving the problems that the diversity of intestinal flora is reduced, the excessive propagation of firmictures, the expression of Bacteroidetes is reduced and the like, which are caused by circadian rhythm disorder, and can be used for preventing and treating the diseases caused by circadian rhythm disorder, so that the ficus striata flavone can be used for preventing and treating the diseases caused by circadian rhythm disorder. Meanwhile, circadian rhythm oscillation of key bacteria such as prevotella, Bacteroides and Clostridium can be adjusted, and increase of the F / B ratio is reduced, so that the rhythm and stability of intestinal flora are improved. The invention simultaneously discloses two preparation processes, namely an ethanol reflux-resin purification method and a water extraction-concentration-alcohol precipitation method, so that the stable quality of the extract is ensured, and the industrial feasibility is realized.

The invention relates to an application of pseudoprevotella griseus in preparation of a medicine for treating inflammatory bowel diseases. The pseudoprevotella griseus (probiotics) medicine can be used for treating the inflammatory bowel disease, and has the effects of relieving colon length shortening, intestinal villus shedding and goblet cell number reduction in the inflammatory bowel disease and relieving inflammation. The medicine has the advantages of small side effect and good curative effect; under the condition of lack of medicines for clinically preventing and treating inflammatory bowel diseases at present, the compound has wide clinical application potential.

The invention discloses hawthorn pectin as well as a preparation method and application thereof, and belongs to the field of medicines. The preparation method comprises the following steps: adding compound enzyme into fresh hawthorn fruit homogenate for enzymolysis, adding probiotics (lactobacillus and bifidobacterium) for fermentation, carrying out alcohol precipitation, separating and purifying, and drying to obtain the hawthorn pectin. The hawthorn pectin can play a role in preventing and / or treating enteritis, remarkably increase the length of colon villus and the thickness of muscular layers of mice with colitis, promote the protein expression of perimembrane protein family protein 1 (ZO-1) and occludin (Occludin), increase the species number of cecum content flora and increase the activity of colitis. According to the present invention, with the application of the cecum extract to the preparation of the cecum extract, the abundance of the Mucispiril bacterial genus, the desulfo vibrio genus, the prevotella genus and the Bilophila genus in the cecum content can be inhibited, and the related metabolic level in the KEGG pathway and the MetaCyc pathway of the cecum content flora can be adjusted;

The present invention aims to provide an intestinal commensal bacterium that increases IgA levels in breast milk. The agent for increasing IgA antibody levels in breast milk comprises one or more strains selected from the following: a Bacteroides strain having a 16S rRNA gene that is at least 90% identical to the nucleotide sequence represented by SEQ ID NO: 1 and increases IgA antibody levels in breast milk; and a Prevotella strain having a 16S rRNA gene that is at least 90% identical to the nucleotide sequence represented by SEQ ID NO: 2 and increases IgA antibody levels in breast milk.

A novel Lactobacillus rhamnosus KBL2290 strain exhibits various activities such as improving intestinal flora, anti-inflammatory, and strengthening intestinal tight junctions. The strain may increase intestinal flora of Akkermansia genus, Lactobacillus genus, Ruminococcus genus or Prevotella genus, suppress an expression of interleukin 1-beta (IL-1B), interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 12p40 (IL-12p40), interleukin 13 (IL-13), or interleukin 17A (IL-17A), suppresses an expression of chemokine ligand 2 (CCL2) or chemokine ligand 1 (CXCL1), suppress an expression of cyclooxygenase 2 (Cox-2) or nitric oxide synthase (iNOS), promote an expression of interleukin 10 (IL-10) or transforming growth factor-β (TGF-β), and increase an expression of Zo-1 or Occludin. A pharmaceutical composition including the strain may prevent or treat inflammatory bowel disease.

The invention relates to a hyperglycemia individual alpha-linolenic acid accurate intervention system based on intestinal flora types, and belongs to the technical field of accurate nutrition and metabolic disease intervention. The flora typing module is used for determining that the intestinal flora type is bacteroid or prevotella; the alpha-linolenic acid supplementing module is used for determining an alpha-linolenic acid supplementing scheme according to the flora typing result; if the intestinal flora type is bacteroid, regulating blood sugar by supplementing alpha-linolenic acid; if the intestinal flora type is a prevotella type, the blood sugar is not regulated by supplementing the alpha-linolenic acid. According to the method, intestinal flora typing is used as a predictive factor of the ALA intervention effect for the first time, and the problems of non-uniform response rate and indefinite effect caused by neglecting individual flora heterogeneity in the prior art are solved.

Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and / or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera Flavonifractor, Dielma, Akkermansia, Alistipes, Bacteroides, Butyricimonas, Vampirovibrio, Tyzzerella, Parabacteroides distasonis, Fournierella, Fournierella massiliensis, Eisenbergiella tayi, Tissierellales, Hungateiclostridium thermocellum, Dorea formicigenerans, Caloramator coolhaasi, Muricomes, Geosporobacter, Prevotella paludivivens, Lactobacillus secaliphilus, Bacteroides finegoldii, Lactobacillus johnsonii, Parapedobacter composti, and Anaerotignum lactatifermentans and wherein the method further comprises treating the subject with a combination of (i) a PD-1, PDL1, or PDL2 inhibitor and (ii) a CTLA-4, B7-1, CN or B7-2 inhibitor.